We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MANUFACTURING VARIATIONS SPARK PANCREATIC EXTRACT CHANGES
Concerns over variations in the formulation, dosage and manufacturing processes of all exocrine pancreatic insufficiency drugs (PIDs) have prompted the FDA to require new marketing applications for such products.